Enlivex Therapeutics (Nasdaq: ENLV)
Our mission is to establish new equilibriums – both in patients' immune responses and in the field of immunotherapy. As a clinical-stage company focused on specialized cell immunotherapy, we intend to develop and commercialize an allogeneic drug pipeline for rebalancing all manner of immune hyper-responses. Our pioneering Allocetra™ cell-based therapy breaks with old paradigms, offering to effectively treat numerous acute conditions through a radically different clinical approach. By using the body's native mechanisms to restore – rather than suppress – immune balance, we aim to reshape the way immune, autoimmune, and inflammatory conditions are both thought of and treated. Highlights: * Advanced clinical-stage pipeline with promising Phase II results * Short regulatory approval pathway * Multi-billion-dollar markets: Post-BMT complications , Sepsis, Solid tumors
- website: http://www.enlivex.com
- twitter: https://twitter.com/EnlivexT
- linkedin: http://www.linkedin.com/company/enlivex-therapeutics-nasdaq-enlv